The etiology mystery in primary biliary cirrhosis

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 105-115

  Selmi, Carlo ^a,b   Gershwin, M Eric ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimitochondrial autoantibodies; Female predominance; Primary biliary cirrhosis

Indexed keywords

ANDROGEN; ANTINUCLEAR ANTIBODY; ESTROGEN; GAMMA INTERFERON; IMMUNOGLOBULIN A; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MITOCHONDRION ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CHROMOSOME ABERRATION; CHROMOSOME INACTIVATION; CYTOKINE PRODUCTION; DISEASE MODEL; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC SUSCEPTIBILITY; HORMONE ACTION; HOST SUSCEPTIBILITY; HUMAN; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SEX DIFFERENCE; X CHROMOSOME;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MITOCHONDRIA, LIVER;

EID: 77952577577     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282073     Document Type: Review

References (40)

1. Kaplan MM, Gershwin ME: Primary biliary cirrhosis. N Engl J Med 2005;353:1261-1273.
2. Ludwig J, Dickson ER, McDonald GS: Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-112.
3. Kim WR, Lindor KD, Locke GR 3rd, et al: Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000;119:1631-1636.
4. Gershwin ME, Selmi C, Worman HJ, et al: Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-1202.
5. Invernizzi P, De Andreis C, Sirchia SM, et al: Blood fetal microchimerism in primary biliary cirrhosis. Clin Exp Immunol 2000;122:418-422.
6. Selmi C: The X in sex: how autoimmune diseases revolve around sex chromosomes. Best Pract Res Clin Rheumatol 2008;22:913-922.
7. Carrel L, Willard HF: X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005;434:400-404.
8. Invernizzi P, Miozzo M, Battezzati PM, et al: Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004;363:533-535. (Pubitemid 38229455)
9. Invernizzi P, Miozzo M, Selmi C, et al: X chromosome monosomy: a common mechanism for autoimmune diseases. J Immunol 2005;175:575-578.
10. Miozzo M, Selmi C, Gentilin B, et al: Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007;46:456-462.
11. Padgett KA, Lan RY, Leung PC, et al: Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009;32:246-253.
12. Sanchez-Pernaute O, Ospelt C, Neidhart M, Gay S: Epigenetic clues to rheumatoid arthritis. J Autoimmun 2008;30:12-20.
13. Hewagama A, Richardson B: The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009;33:3-11.
14. Ozbalkan Z, Bagislar S, Kiraz S, et al: Skewed X chromosome inactivation in blood cells of women with scleroderma. Arthritis Rheum 2005;52:1564-1570.
15. Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel R L: Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210-225.
16. Gershwin ME, Mackay IR, Sturgess A, Coppel RL: Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987;138:3525-3531.
17. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J: Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005;25:298-310. (Pubitemid 41254577)
18. Lan RY, Cheng C, Lian ZX, et al: Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006;43:729-737.
19. Selmi C, Lleo A, Pasini S, Zuin M, Gershwin ME: Innate immunity and primary biliary cirrhosis. Curr Mol Med 2009;9:45-51.
20. Pares A, Caballeria L, Rodes J, et al: Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000;32:561-566.
21. Mattner J, Savage PB, Leung P, et al: Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008;3:304-315.
22. Selmi C, Mayo MJ, Bach N, et al: Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004;127:485-492.
23. Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME: Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 2005;25:265-280.
24. Invernizzi P, Gershwin ME: The genetic basis of primary biliary cirrhosis: premises, not promises. Gastroenterology 2008;135:1044-1047.
25. Hirschfield GM, Liu X, Xu C, et al: Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009;360:2544-2555.
26. Bogdanos DP, Vergani D: Bacteria and Primary Biliary Cirrhosis. Clin Rev Allergy Immunol 2009;36:30-39.
27. Selmi C, Balkwill DL, Invernizzi P, et al: Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003;38:1250-1257.
28. Long SA, Quan C, Van de Water J, et al: Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol 2001;167:2956-2963.
29. Oertelt S, Ridgway WM, Ansari AA, Coppel RL, Gershwin ME: Murine models of primary biliary cirrhosis: comparisons and contrasts. Hepatol Res 2007;37(suppl 3):S365- S369.
30. Oertelt S, Lian ZX, Cheng CM, et al: Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006;177:1655-1660.
31. Moritoki Y, Zhang W, Tsuneyama K, et al: B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 2009;136:1037-1047.
32. Wakabayashi K, Lian ZX, Moritoki Y, et al: IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology 2006;44:1240-1249.
33. Amano K, Leung PS, Xu Q, et al: Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol 2004;172:6444-6452.
34. Wakabayashi K, Lian ZX, Leung PS, et al: Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 2008;48:531-540.
35. Wakabayashi K, Yoshida K, Leung PS, et al: Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol 2009;155:577-586.
36. Ir ie J, Wu Y, Wicker LS, et al: NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006;203:1209-1219.
37. Longhi MS, Meda F, Wang P, Samyn M, Mieli-Vergani G, Vergani D, Ma Y: Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008;47:581-591.
38. Chuang YH, Lian ZX, Yang GX, Shu SA, Moritoki Y, Ridgway WM, Ansari AA, Kronenberg M, Flavell RA, Gao B, Gershwin ME: Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 2008;47:571-580.
39. Leung PS, Park O, Tsuneyama K, Kurth MJ, Lam KS, Ansari AA, Coppel RL, Gershwin ME: Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 2007;179:2651-2657.
40. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A: Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001;108:223-232.